Acute Ischemic Tissue Evolution and Implications for Imaging Selection of Patients for Therapy and Clinical Trials using Sex-Disaggregated Data
急性缺血组织的演变以及对使用按性别分类数据进行治疗和临床试验的患者影像学选择的影响
基本信息
- 批准号:10818647
- 负责人:
- 金额:$ 6.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-21 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAgeAlgorithmsAnteriorBiologicalBlood flowBrainBrain InfarctionCell SurvivalClinicalClinical TrialsCollateral CirculationDataData SetDiagnosticDiseaseDisparityDropsEligibility DeterminationEtiologyEvolutionGlucoseGoalsGrowthHealthHourImageInfarctionInjuryIschemiaIschemic StrokeKnowledgeLesionLinear ModelsMeasuresMissionModelingNational Institute of Neurological Disorders and StrokeNervous SystemOutcomePatient Outcomes AssessmentsPatient SelectionPatientsPerformancePerfusionPhysiologicalReperfusion TherapyResearchScanningSelection for TreatmentsSeveritiesSex DifferencesSourceStrokeSymptomsTestingTimeTissuesTreatment EfficacyWomanWorkage effectbiological sexbrain tissuecerebral hemodynamicsclinical practiceclinically relevantcohortdisabilityexperiencefollow-uphypoperfusionimage processingimaging biomarkerimprovedmalemennervous system disorderoptimal treatmentsperfusion imagingrecruitsecondary analysissexsex disparitysexual dimorphismstandard of carestemstroke patientstroke therapystudy populationtreatment guidelines
项目摘要
Current clinical practice treats stroke without regard to potential sex differences. Is this the best approach?
Standard of care image processing thresholds are uniformly applied across all patients to identify potentially
salvageable versus irreversibly infarcted brain tissue. However, women experience ischemic stroke differently
than men with known physiological differences originating at the cellular level. As such, the long-term research
goal is to characterize acute ischemic tissue evolution for men and women in the context of personalized imaging
selection of patients for acute reperfusion therapy and trials.
It is well established that the benefit of treatment for acute ischemic stroke declines with longer onset to
treatment times. Delayed patient presentation is the major treatment limitation with only one-third of all acute
ischemic stroke patients presenting within 8 hours of symptoms. Sex disparities exist in ischemic stroke. Women
have worse functional and patient-reported outcomes. Although women's higher age, greater stroke severity,
and poorer health at the time of stroke partially explain these disparities, a substantial knowledge gap remains.
Women present more often with treatable ischemic strokes than men. Women also have better-functioning
collateral networks and slower infarct growth untreated. Why do women suffer from more disability if they are
presenting with favorable imaging profiles? Does this paradox stem from the imaging-defined thresholds used
to identify infarcted tissue and potentially salvageable tissue? Could these thresholds differ for men and women?
Recent trials have demonstrated the utility of imaging thresholds to identify patients that will respond to treatment
If the optimal thresholds for ischemic core, salvageable penumbra, and time from onset are different for men and
women, are we denying patients the benefits of treatment by not incorporating sex-specific treatment thresholds
into treatment selection algorithms?
In line with NINDS's mission to seek fundamental knowledge about the brain and nervous system and to use
that knowledge to reduce the burden of neurological disease, this project proposes to addresses these
knowledge gaps and test the hypothesis that acute ischemic tissue evolution is different between men and
women. Imaging features of cerebral hemodynamics will be directly related to infarct evolution to evaluate sex
differences in acute ischemic stroke in the context of imaging selection of patients for acute reperfusion therapy
and trials. This will address the paucity of studies on sex differences in ischemic stroke, overcoming limitations
in translational relevance of clinical trials. The proposed project will result in generalizable evidence on the
influence of sex on ischemic tissue evolution and inform on the selection of imaging-based thresholds currently
used to identify infarcted tissue and potentially salvageable tissue. Establishing evidence of sex differences in
objective imaging biomarkers is a step toward further refining the individualized imaging selection of patients for
acute reperfusion therapy and trials.
目前的临床实践治疗中风时不考虑潜在的性别差异。这是最好的方法吗?
护理标准图像处理阈值统一应用于所有患者,以识别潜在的
可挽救的梗塞脑组织与不可逆的梗塞脑组织。然而,女性经历缺血性中风的方式不同
与具有源自细胞水平的已知生理差异的男性相比。因此,长期研究
目标是在个性化成像的背景下描述男性和女性的急性缺血组织演变特征
选择患者进行急性再灌注治疗和试验。
众所周知,急性缺血性中风的治疗效果随着发病时间的延长而下降。
治疗次数。患者就诊延迟是主要的治疗限制,仅占所有急性患者的三分之一
缺血性中风患者在出现症状后 8 小时内出现症状。缺血性中风存在性别差异。女性
具有更差的功能和患者报告的结果。尽管女性年龄较大,中风严重程度较高,
中风时健康状况不佳部分解释了这些差异,但仍然存在巨大的知识差距。
女性比男性更容易出现可治疗的缺血性中风。女性也有更好的机能
未经治疗的侧支网络和梗塞生长缓慢。为什么女性会遭受更多的残疾?
呈现良好的成像轮廓?这个悖论是否源于所使用的成像定义阈值
识别梗塞组织和可能可挽救的组织?男性和女性的这些阈值会有所不同吗?
最近的试验证明了成像阈值可用于识别对治疗有反应的患者
如果男性和女性的缺血核心、可挽救半暗带和发病时间的最佳阈值不同
女性,我们是否因为不考虑性别特异性治疗阈值而剥夺了患者治疗的益处
进入治疗选择算法?
根据 NINDS 的使命,寻求有关大脑和神经系统的基础知识并使用
该项目建议解决这些问题
知识差距并检验男性和女性之间急性缺血组织进化不同的假设
女性。脑血流动力学的影像学特征将与梗塞演变直接相关以评估性别
急性缺血性卒中在急性再灌注治疗患者影像学选择方面的差异
和考验。这将解决缺血性中风性别差异研究的缺乏问题,克服局限性
临床试验的转化相关性。拟议的项目将产生关于以下问题的普遍证据:
性别对缺血组织进化的影响以及目前基于成像的阈值选择的信息
用于识别梗塞组织和可能可挽救的组织。建立性别差异的证据
客观成像生物标志物是进一步完善患者个体化成像选择的一步
急性再灌注治疗和试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adrienne Nicole Dula其他文献
Adrienne Nicole Dula的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adrienne Nicole Dula', 18)}}的其他基金
Acute Ischemic Tissue Evolution and Implications for Imaging Selection of Patients for Therapy and Clinical Trials using Sex-Disaggregated Data
急性缺血组织的演变以及对使用按性别分类数据进行治疗和临床试验的患者影像学选择的影响
- 批准号:
10575791 - 财政年份:2022
- 资助金额:
$ 6.02万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 6.02万 - 项目类别:
Research Grant














{{item.name}}会员




